SCHEMBL4405249

SCHEMBL4405249

CC(=O)Oc1ccc(C(C)Br)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.55
MAPT P10636 3/20 0.50
POLB P06746 1/20 0.50
PKM P14618 1/20 0.50
ESR1 P03372 3/20 0.49
KDM4E B2RXH2 3/20 0.49
CYP3A4 P08684 3/20 0.49
HIF1A Q16665 2/20 0.49
SLC6A3 Q01959 2/20 0.49
ABCB11 O95342 1/20 0.49
ADRA2A P08913 1/20 0.49
CYP2C9 P11712 1/20 0.49
TSHR P16473 1/20 0.49
PDE4A P27815 1/20 0.49
ADRA1A P35348 1/20 0.49
OPRK1 P41145 1/20 0.49
STAT6 P42226 1/20 0.49
GPR55 Q9Y2T6 1/20 0.49
ELANE P08246 4/20 0.48
HSD17B10 Q99714 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11585781 0.86 LMNA (0.57) LMNAMAPTPOLBPKMESR1
SCHEMBL1714626 0.83 LMNA (0.59) LMNAMAPTPOLBPKMESR1
SCHEMBL9506851 0.83 LMNA (0.59) LMNAMAPTPOLBPKMESR1
SCHEMBL29013798 0.82 LMNA (0.53) LMNAMAPTPOLBPKMESR1
SCHEMBL8308368 0.82 LMNA (0.53) LMNAMAPTPOLBPKMESR1
SCHEMBL11791125 0.82 LMNA (0.57) LMNAMAPTPOLBPKMESR1
SCHEMBL15614010 0.82 LMNA (0.57) LMNAMAPTPOLBPKMESR1
SCHEMBL1454538 0.82 LMNA (0.57) LMNAMAPTPOLBPKMESR1
Hydrogen Peroxide SCHEMBL9578945 0.82 LMNA (0.57) LMNAMAPTPOLBPKMESR1
SCHEMBL24747284 0.81 LMNA (0.62) LMNAMAPTPOLBPKMESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240009169-A9 PPARG Modulators for the Treatment of Osteoporosis UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2024-01-11 US disclosed
US-20230072933-A1 PPARG Modulators for the Treatment of Osteoporosis SCRIPPS RESEARCH INST (US) 2023-03-09 US disclosed
US-20230072933-A1 PPARG Modulators for the Treatment of Osteoporosis SCRIPPS RESEARCH INST (US) 2023-03-09 US disclosed
US-10744117-B2 PPARG modulators for the treatment of osteoporosis THE SCRIPPS RESEARCH INSTITUTE (US) 2020-08-18 US disclosed
US-10744117-B2 PPARG modulators for the treatment of osteoporosis THE SCRIPPS RESEARCH INSTITUTE (US) 2020-08-18 US disclosed
US-20180369196-A1 PPARG Modulators for the Treatment of Osteoporosis UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2018-12-27 US disclosed
US-10016394-B2 PPARG modulators for treatment of osteoporosis THE SCRIPPS RESEARCH INSTITUTE (US) 2018-07-10 US disclosed
US-10016394-B2 PPARG modulators for treatment of osteoporosis THE SCRIPPS RESEARCH INSTITUTE (US) 2018-07-10 US disclosed
US-10016394-B2 PPARG modulators for treatment of osteoporosis THE SCRIPPS RESEARCH INSTITUTE (US) 2018-07-10 US disclosed
US-20170035730-A1 PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2017-02-09 US disclosed
US-9051265-B2 N-benzylindole modulators of PPARG THE SCRIPPS RESEARCH INSTITUTE (US) 2015-06-09 US disclosed
CN-101258143-B Benzylpiperazine derivatives and their medical use GLAXO GROUP LTD 2012-12-26 CN disclosed
WO-2012170561-A1 N-BENZYLINDOLE MODULATORS OF PPARG THE SCRIPPS RESEARCH INSTITUTE (T.S.R.I.) (US) 2012-12-13 WO disclosed
WO-2012170561-A1 N-BENZYLINDOLE MODULATORS OF PPARG THE SCRIPPS RESEARCH INSTITUTE (T.S.R.I.) (US) 2012-12-13 WO disclosed
US-20120309769-A1 N-BENZYLINDOLE MODULATORS OF PPARG SCRIPPS RESEARCH INSTITUTE, THE (US) 2012-12-06 US disclosed
US-20120309769-A1 N-BENZYLINDOLE MODULATORS OF PPARG SCRIPPS RESEARCH INSTITUTE, THE (US) 2012-12-06 US disclosed
US-20120309769-A1 N-BENZYLINDOLE MODULATORS OF PPARG SCRIPPS RESEARCH INSTITUTE, THE (US) 2012-12-06 US disclosed
US-8168667-B2 Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such GALAPAGOS NV (BE) 2012-05-01 US disclosed
US-20100210699-A1 IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH DART THERAPUTICS, LLC. 2010-08-19 US disclosed
CN-101258143-A Benzylpiperazine derivatives and their medical use GLAXO GROUP LTD (GB) 2008-09-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170035730-A1 PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS PPARG, PPARA, PPARD LMNA 2152/4885MAPT 3261/4885POLB 3223/4885
US-10016394-B2 PPARG modulators for treatment of osteoporosis PPARG, PPARA, PPARD LMNA 2152/4885MAPT 3261/4885POLB 3223/4885
US-20100210699-A1 IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH NR5A1, AR, HSD17B7 LMNA 4085/4885MAPT 4672/4885POLB 4342/4885
US-20120309769-A1 N-BENZYLINDOLE MODULATORS OF PPARG PPARG, CDK5R1, CDK5 LMNA 483/4885MAPT 3591/4885POLB 2382/4885
US-20230072933-A1 PPARG Modulators for the Treatment of Osteoporosis PPARG, PPARA, PPARD LMNA 2029/4885MAPT 2764/4885POLB 3325/4885
US-20180369196-A1 PPARG Modulators for the Treatment of Osteoporosis PPARG, PPARA, PPARD LMNA 2029/4885MAPT 2764/4885POLB 3325/4885
US-10744117-B2 PPARG modulators for the treatment of osteoporosis PPARG, PPARA, PPARD LMNA 2029/4885MAPT 2764/4885POLB 3325/4885
US-20240009169-A9 PPARG Modulators for the Treatment of Osteoporosis PPARG, PPARA, PPARD LMNA 2029/4885MAPT 2764/4885POLB 3325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.